ArticleFrontiers in microbiology2021
Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors.
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Pooled it
- Widespread SARS-CoV-2 Transmission Despite Limited Reported Cases and Clinical Disease: Exploring the Role of Pre-Existing Humoral Immunity to SARS-CoV-2 in Eastern Sierra Leone.Immunity, inflammation and disease · 2026Article
- Acquisition of Humoral Immune Responses in Convalescent Japanese People with SARS-CoV-2 (COVID-19) Infection in 2021.Viruses · 2023Article
- Specific COVID-19 risk behaviors and the preventive effect of personal protective equipment among healthcare workers in Japan.Global health & medicine · 2023Article
- RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers.Microbiology spectrum · 2023Article
- Prediction models for neutralization activity against emerging SARS-CoV-2 variants: A cross-sectional study.Frontiers in microbiology · 2023Article
- A case of reinfection with a different variant of SARS-CoV-2: case report.The Egyptian journal of internal medicine · 2023Article
- A Cellular Assay for Spike/ACE2 Fusion: Quantification of Fusion-Inhibitory Antibodies after COVID-19 and Vaccination.Viruses · 2022Article
- Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology.Journal of molecular cell biology · 2022Review
- Time dependent decline of neutralizing antibody titers in COVID-19 patients from Pune, India and evidence of reinfection.Microbes and infection · 2022Article
- Article
- Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions.Translational research : the journal of laboratory and clinical medicine · 2022Review
- Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection.Open forum infectious diseases · 2022Article
- Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.Journal of molecular cell biology · 2022Article
- Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections.Internal medicine (Tokyo, Japan) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.